Priyanka Mohan Lal

Priyanka Mohan Lal

Auto-generated profile, based on publicly available information

Priyanka Mohan Lal

Department of Internal Medicine, Ziauddin University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AMAnmol Mohan
Anmol Mohan
RHRamsha Haider
Ramsha Haider
HFHajar Mbbs Fakhor
Hajar Mbbs Fakhor
FHFnu Mbbs Hina
Fnu Mbbs Hina
VKVikash Kumar
Vikash Kumar
SKSaka Kazeem
Saka Kazeem
A common health problem known as polycystic ovarian syndrome (PCOS), is characterized by irregular periods, an excess of androgen production, and polycystic ovaries. It is one of the most prevalent endocrine disorders in women of reproductive age, affecting 4–20% of women worldwide. Numerous studies have found a connection between the onset and symptoms of PCOS and Vitamin D insufficiency. Vitamin D insufficiency causes calcium dysregulation and follicular arrest in women with PCOS, which is connected to menstrual irregularities and fertility issues. Studies have connected PCOS metabolic alterations to VDR polymorphisms such as iApa-I, Taq-I, Cdx2, and Fok-I. Insulin resistance is directly related to Vitamin D, is one of the most distinctive characteristics of the PCOS phenotype. Thus, it is suggested that Vitamin D therapy may help PCOS patients with their insulin sensitivity. In addition to insulin resistance, cardiovascular issues are a second metabolic disturbance that PCOS patients with low Vitamin D levels experience. Dyslipidemia is not linked to an increased risk of cardiovascular disease in PCOS-affected women. Vitamin D dramatically improves glucose metabolism by increasing insulin production, insulin receptor expression and reducing pro-inflammatory cytokines. The effect of Vitamin D on the metabolic and reproductive dysfunctions associated with PCOS may be mediated by an overall impact on insulin resistance. Vitamin D supplementation improved menstrual periods, increased folliculogenesis, and decreased blood testosterone levels in PCOS patients, all of which had a significant impact on the ability to procreate. As a result, it might be a cutting-edge therapeutic strategy for treating PCOS concurrently.

17 January 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SBSamia Rauf Mbbs Butt
Samia Rauf Mbbs Butt
ASAmna Mbbs Soulat
Amna Mbbs Soulat
PLPriyanka Mohan Mbbs Lal
Priyanka Mohan Mbbs Lal
HFHajar Fakhor
Hajar Fakhor
SPSiddharth Kumar Patel
Siddharth Kumar Patel
Sarwan KumarSarwan Kumar
Sarwan Kumar
Endometrial cancer is one of the most prevalent tumours in females and holds an 83% survival rate within 5 years of diagnosis. Hypoestrogenism is a major risk factor for the development of endometrial carcinoma (EC) therefore two major types are derived, type 1 being oestrogen-dependent and type 2 being oestrogen independent. Surgery, chemotherapeutic drugs, and radiation therapy are only a few of the treatment options for EC. Treatment of gynaecologic malignancies greatly depends on diagnosis or prognostic prediction. Diagnostic imaging data and clinical course prediction are the two core pillars of artificial intelligence (AI) applications. One of the most popular imaging techniques for spotting preoperative endometrial cancer is MRI, although this technique can only produce qualitative data. When used to classify patients, AI improves the effectiveness of visual feature extraction. In general, AI has the potential to enhance the precision and effectiveness of endometrial cancer diagnosis and therapy. This review aims to highlight the current status of applications of AI in endometrial cancer and provide a comprehensive understanding of how recent advancements in AI have assisted clinicians in making better diagnosis and improving prognosis of endometrial cancer. Still, additional study is required to comprehend its strengths and limits fully.

1 June 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
AMAnmol Mohan
Anmol Mohan
HFHajar Fakhor
Hajar Fakhor
NNNirav Nimavat
Nirav Nimavat
UWUm- Ul- Wara
Um- Ul- Wara
PLPriyanka Mohan Lal
Priyanka Mohan Lal
MEMohammad Yasir Essar
Mohammad Yasir Essar

22 April 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
PLPriyanka Mbbs Mohan Lal
Priyanka Mbbs Mohan Lal
MSMuhammad Mbbs Hamza Siddiqui
Muhammad Mbbs Hamza Siddiqui
ASAmna Mbbs Soulat
Amna Mbbs Soulat
AMAnmol Mohan
Anmol Mohan
DTDev Mbbs Tanush
Dev Mbbs Tanush
UTUsha Tejwaney
Usha Tejwaney
Breast cancer (BC), a complex and varied ailment, poses a significant global health burden. MicroRNAs (miRNAs) have emerged as vital regulators in BC progression, with potential implications for diagnosis and treatment. This review aims to synthesize current insights into miRNA dysregulation in BC. MiRNAs, small RNA molecules, govern gene expression post-transcriptionally and are implicated in BC initiation, metastasis, and therapy resistance. Differential expression of specific miRNAs in BC tissues versus normal breast tissue sheds light on underlying molecular mechanisms. MiRNAs also offer promise as diagnostic biomarkers due to their stable nature, accessibility in bodily fluids, and altered expression patterns in early-stage disease, augmenting conventional diagnostic methods. Beyond diagnosis, miRNAs also hold promise as therapeutic targets in BC. By modulating the expression of specific dysregulated miRNAs, it may be possible to restore normal cellular functions and overcome treatment resistance. However, several challenges need to be addressed before miRNA-based therapies can be translated into clinical practice, including the development of efficient delivery systems and rigorous evaluation through preclinical and clinical trials. MiRNAs represent a promising avenue in BC research, offering potential applications in diagnosis, prognosis, and therapeutic interventions. As our understanding of miRNA biology deepens and technology advances, further research and collaborative efforts are needed to fully exploit the diagnostic and therapeutic potential of miRNAs in BC management. Ultimately, the integration of miRNA-based approaches into clinical practice may lead to more personalized and effective strategies for combating this devastating disease.

21 October 2021 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
AMAnmol Mohan
Anmol Mohan
MSMuhammad Taha Arshad Shaikh
Muhammad Taha Arshad Shaikh
UWUm-Ul Wara
Um-Ul Wara
SRSudhan Rackimuthu
Sudhan Rackimuthu
ACAna Carla dos Santos Costa
Ana Carla dos Santos Costa
MEMohammad Yasir Essar
Mohammad Yasir Essar
In Pakistan, HIV has increased at an alarming rate in recent decades, and the death toll has risen. It is a public health challenge amidst the COVID-19 pandemic that is not being given due importance. The present article looks at the challenges and efforts being made to deal with HIV among children in Ratodero, Pakistan, and addresses measures that can be taken to control the disease in the child population epidemiologically.

7 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AMAnmol Mohan
Anmol Mohan
ZHZim Warda Hasan
Zim Warda Hasan
HGHetvi Gordhan Galani
Hetvi Gordhan Galani
TATahniat Afroze
Tahniat Afroze
RNRukash Khan Niazi
Rukash Khan Niazi
Sarwan KumarSarwan Kumar
Sarwan Kumar
The global rise in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) represents a critical and intertwined public health challenge. Both conditions share overlapping mechanisms, such as insulin resistance, lipid toxicity, chronic inflammation, and mitochondrial dysfunction, that drive disease progression and worsen outcomes. This review synthesizes emerging evidence on the bidirectional relationship between T2DM and MASLD, with a specific focus on underrecognized clinical intersections, including hepatogenous diabetes and the role of subclinical liver injury in diabetic patients. Unlike prior reviews, it emphasizes mechanistic links involving advanced glycation end products, cytokine dysregulation, and microvascular dysfunction, highlighting their implications for both hepatic and extrahepatic complications. We summarize epidemiological trends, outline gaps in current screening practices, and assess therapeutic strategies ranging from glycemic control and hepatoprotective antidiabetic agents to liver-directed interventions. Key takeaways for clinicians include the importance of early, integrated liver fibrosis assessment in diabetic care and the need for multidisciplinary approaches to reduce risks of cirrhosis, hepatocellular carcinoma, and mortality. By bridging pathophysiological insights with practical screening and treatment considerations, this review aims to guide more proactive and coordinated management of patients affected by T2DM and MASLD.